Literature DB >> 16212643

Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?

Rafael Barcena1, Elena Oton, Maria Angeles Moreno, Jesús Fortún, Miguel Garcia-Gonzalez, Ana Moreno, Emilio de Vicente.   

Abstract

Antituberculous treatment is a well-known cause of fulminant hepatic failure (FHF). This could lead to liver transplantation as the only possible treatment, which on the other hand could be contraindicated due to active tuberculosis. The risk of aggressive dissemination of the disease after transplantation is not clearly determined by the current second-line antituberculous therapies. We report a case of vertebral tuberculosis treated with rifampin, isoniazid and pyrazinamide. He developed an FHF that was treated with urgent liver transplantation. Despite the immunosuppression, the disease was well controlled with ciprofloxacin, ethambutol and streptomycin and the patient is in good health 23 months after transplantation. In conclusion, active extrapulmonary tuberculosis should perhaps be considered for liver transplantation when FHF develops due to anti-tuberculous drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212643     DOI: 10.1111/j.1600-6143.2005.01065.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  3 in total

Review 1.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

2.  The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995-2013).

Authors:  Andrés González-García; Jesús Fortún; Enrique Elorza Navas; Pilar Martín-Dávila; Marta Tato; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

3.  Liver Transplantation in Antituberculosis Drugs-Induced Fulminant Hepatic Failure: A Case Report and Review of the Literature.

Authors:  Xiaoyan Li; Yujie Liu; Erhong Zhang; Qiong He; Yong-Bo Tang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.